GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (GMI), a clinical stage pharmaceutical company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced it has successfully completed two Phase 1 safety studies of its lead drug candidate GMI-1070 for vaso-occlusive crisis of sickle cell disease. Clinical investigators report no serious adverse events in either of the two studies.
